Table 2.
Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Smigiel et al. (2018) | Monfrini et al. (2019) | Monfrini et al. (2019) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gender | Male | Male | Female | Male | Male | Male | Male | Female | Female | Male | Female | Female | Male |
Origin | Moroccan | American | American | Arab Iraqi | Israeli | Israeli | Saudi Arabian | Saudi Arabian | Algerian | Algerian | Polish | Italian | Italian |
Current age | 4 years | 1 year and 6 months | 10 years | 3 years | 12 years | 16 years | 2 years 6 months | 4 months (at time of death) | 21 years | 16 years | 1 year | 22 years | 15 years |
Variant | c.2080C>A; p.P694T | c.2816delC; p.P939Ter | c.2816delC; p.P939Ter | c.388A>G; p.N130D | c.2458T>C; p.S820P | c.2458T>C; p.S820P | c.1076G>C; p.R359P | c.1076G>C; p.R359P | c.3230T>C: p.V1077A | c.3230T>C: p.V1077A | c.2491C>T; p.R831Ter | c.3365T>A; p.V1122E | c.3365T>A; p.V1122E |
Age at onset of initial symptoms | Neonatal hypotonia | Neonatal hypotonia | Neonatal hypotonia | Neonatal hypotonia | Hypotonia during the first 6 months of life | Hypotonia during the first 2 months of life | Hypotonia during first 3 months of life | Hypotonia during first 3 months of life | Neonatal hypotonia | Hypotonia/ataxia started at 15–16 months | Congenital hypotonia, amimia, areflexia | Spastic limb hyperotnia, hyperreflexia | Episodes of aggression, intense anxiety |
Developmental delay | + | + | + | + | + | + | + | + | + | + | + | + | + |
Intellectual disability | + | + | + | + | + | + | + | + | + | + | _ | _ | + |
Speech impairment | + | + | + | + | + | + | + | + | + | + | NA | + | + |
Hypotonia / weakness | + | + | + | + | + | + | + | + | + | + | + | + | + |
Neurological examination | Weakness, absent reflex, abnormal sensation, no walk | Weakness, absent reflex, no walk | Weakness, no walk | Weakness, no walk | Weakness, no walk | Weakness, no walk | Weakness, no walk | Weakness, no walk | No walk | Walk with a walking frame | Contractures of fingers and toes, no reaction to touch or pain | Psychomotor delay, cerebellar syndrome, hyperreflexia, spasticity, dysphagia, myoclonic jerks | Psychomotor delay, cerebellar syndrome, anxiety, aggression |
Sensory NCS | Reduced CV, normal Amp | NT | NT | NT | SSR in hand and food | NT | Normal | NT | Normal CV, reduced Amp in ulnar nerve | Normal | reduced CV | Reduced CV (except normal CV and reduced Amp median nerve) | Marginally reduced CV |
Motor NCS | Reduced CV (except normal CV ulnar nerve), normal Amp (except peroneal nerve reduced) | NT | Severely reduced CV, normal Amp (except peroneal nerve reduced) | NT | NT | NT | Normal | NT | Normal | Normal | NT | Reduced CV (except normal CV ulnar nerve) | Reduced CV |
EMG | NT | NT | Acute and chronic denervation, PSW | NT | NT | NT | Normal | NT | Chronic denervation- reinnervation | Chronic denervation- reinnervation | NT | NT | NT |
MRI | Atrophic changes and white matter loss | Cerebral white matter loss | Cerebral white matter loss. Severe atrophy of corpus callosum | NT | Normal | Normal | Diffuse white matter T2 hyperintensity | NT | Cerebellar atrophy | Cerebellar atrophy | Ischaemic and hypoxic changes | Mild cerebellar atrophy, mild diffuse white matter T2 hyperintensity | Mild diffuse white matter T2 hyperintensity |
− = absent; + = present; Amp = amplitude; CV = conduction velocity/velocities; NA = not applicable; NCS = nerve conduction studies; NT = not tested; PSW = positive sharp waves; SSR = sympathetic skin response.